Per- and Polyfluoroalkyl Substance Plasma Concentrations and Bone Mineral Density in Midchildhood: A Cross-Sectional Study (Project Viva, United States)
暂无分享,去创建一个
B. Coull | C. Gordon | A. Calafat | S. Sagiv | D. Gold | S. Rifas-Shiman | X. Ye | E. Oken | C. Rosen | Rachel Cluett | A. Fleisch | S. Seshasayee | L. B. Rokoff
[1] Jessica G. Young,et al. Body composition and bone mineral density in childhood. , 2019, Bone.
[2] Roberta F. White,et al. Prenatal and childhood exposure to per- and polyfluoroalkyl substances (PFASs) and child cognition. , 2018, Environment international.
[3] S. Grant,et al. Genetically Determined Later Puberty Impacts Lowered Bone Mineral Density in Childhood and Adulthood , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] A. Calafat,et al. Early life exposure to per- and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels. , 2018, Environment international.
[5] Ramzi W. Nahhas,et al. Perfluoroalkyl substances, bone density, and cardio‐metabolic risk factors in obese 8–12 year old children: A pilot study , 2018, Environmental research.
[6] A. Calafat,et al. Per- and polyfluoroalkyl substances in sera from children 3 to 11 years of age participating in the National Health and Nutrition Examination Survey 2013-2014. , 2018, International journal of hygiene and environmental health.
[7] P. Lehenkari,et al. Perfluoroalkyl substances in human bone: concentrations in bones and effects on bone cell differentiation , 2017, Scientific Reports.
[8] A. Calafat,et al. Predictors of Per- and Polyfluoroalkyl Substance (PFAS) Plasma Concentrations in 6-10 Year Old American Children. , 2017, Environmental science & technology.
[9] A. Calafat,et al. Early-Life Exposure to Perfluoroalkyl Substances and Childhood Metabolic Function , 2016, Environmental health perspectives.
[10] T. Wren,et al. The Determinants of Peak Bone Mass. , 2017, The Journal of pediatrics.
[11] Hea‐Young Cho,et al. Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[12] T. K. Jensen,et al. Longitudinal Associations of Exposure to Perfluoroalkylated Substances in Childhood and Adolescence and Indicators of Adiposity and Glucose Metabolism 6 and 12 Years Later: The European Youth Heart Study , 2016, Diabetes Care.
[13] S. Grant,et al. Physical Activity Benefits the Skeleton of Children Genetically Predisposed to Lower Bone Density in Adulthood , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] K. Kannan,et al. Association of Perfluoroalkyl Substances, Bone Mineral Density, and Osteoporosis in the U.S. Population in NHANES 2009–2010 , 2015, Environmental health perspectives.
[15] A. Calafat,et al. Sociodemographic and Perinatal Predictors of Early Pregnancy Per- and Polyfluoroalkyl Substance (PFAS) Concentrations. , 2015, Environmental science & technology.
[16] T. Hughes,et al. Pharmacological Repression of PPARγ Promotes Osteogenesis , 2015, Nature Communications.
[17] Kazuo Kobayashi-Hattori,et al. Perfluorooctanoic acid binds to peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation in 3T3-L1 adipocytes , 2015, Bioscience, biotechnology, and biochemistry.
[18] Chris Gennings,et al. Characterization of Weighted Quantile Sum Regression for Highly Correlated Data in a Risk Analysis Setting , 2014, Journal of Agricultural, Biological, and Environmental Statistics.
[19] A. Baccarelli,et al. Cohort profile: project viva. , 2015, International journal of epidemiology.
[20] T. Wren,et al. Longitudinal tracking of dual-energy X-ray absorptiometry bone measures over 6 years in children and adolescents: persistence of low bone mass to maturity. , 2014, The Journal of pediatrics.
[21] C. Gordon,et al. 2013 Pediatric Position Development Conference: executive summary and reflections. , 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[22] Pau-Chung Chen,et al. Negative association between serum perfluorooctane sulfate concentration and bone mineral density in US premenopausal women: NHANES, 2005-2008. , 2014, The Journal of clinical endocrinology and metabolism.
[23] C. Gordon,et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. , 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[24] Damià Barceló,et al. Accumulation of perfluoroalkyl substances in human tissues. , 2013, Environment international.
[25] E. Bonefeld‐Jørgensen,et al. Perfluorinated compounds affect the function of sex hormone receptors , 2013, Environmental Science and Pollution Research.
[26] Susan Y. Smith,et al. Combined activation of PPAR-gamma and PPAR-alpha reduces the negative effects of PPAR-gamma agonism on bone and may attenuate PPAR-gamma-mediated loss of bone strength , 2012 .
[27] T. Hangartner,et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. , 2011, The Journal of clinical endocrinology and metabolism.
[28] Mark J. Strynar,et al. Polyfluorinated compounds: past, present, and future. , 2011, Environmental science & technology.
[29] A. Bergman,et al. Tissue distribution of ³⁵S-labelled perfluorooctane sulfonate in adult mice after oral exposure to a low environmentally relevant dose or a high experimental dose. , 2011, Toxicology.
[30] J. Reseland,et al. The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats , 2011, BMC endocrine disorders.
[31] G. Leonardi,et al. Association of Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) with age of puberty among children living near a chemical plant. , 2011, Environmental science & technology.
[32] C. Camargo,et al. A nested case-control study of first-trimester maternal vitamin D status and risk for spontaneous preterm birth. , 2011, American journal of perinatology.
[33] T. Wren,et al. Age at onset of puberty predicts bone mass in young adulthood. , 2011, The Journal of pediatrics.
[34] R. Ge,et al. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances. , 2010, Chemico-biological interactions.
[35] C. Lau,et al. Developmental Effects of Perfluorononanoic Acid in the Mouse Are Dependent on Peroxisome Proliferator-Activated Receptor-Alpha , 2010, PPAR research.
[36] S. Cole,et al. Illustrating bias due to conditioning on a collider. , 2010, International journal of epidemiology.
[37] S. Khosla,et al. Androgens and bone , 2009, Steroids.
[38] C. Gordon,et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[39] Ann V Rowlands,et al. The Measurement and Interpretation of Children's Physical Activity. , 2007, Journal of sports science & medicine.
[40] B. Zemel,et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. , 2007, The Journal of clinical endocrinology and metabolism.
[41] A. Calafat,et al. Serum concentrations of 11 polyfluoroalkyl compounds in the u.s. population: data from the national health and nutrition examination survey (NHANES). , 2007, Environmental science & technology.
[42] John P. Vanden Heuvel,et al. Differential Activation of Nuclear Receptors by Perfluorinated Fatty Acid Analogs and Natural Fatty Acids: A Comparison of Human, Mouse, and Rat Peroxisome Proliferator-Activated Receptor-α, -β, and -γ, Liver X Receptor-β, and Retinoid X Receptor-α , 2006 .
[43] Ravinder J. Singh,et al. C-3 Epimers Can Account for a Significant Proportion of Total Circulating 25-hydroxyvitamin D in Infants, Complicating Accurate Measurement and Interpretation of Vitamin D Status , 2022 .
[44] J. Reginster,et al. Osteoporosis: a still increasing prevalence. , 2005, Bone.
[45] Rhonda A. Brownbill,et al. Measuring body composition in overweight individuals by dual energy x-ray absorptiometry , 2005, BMC Medical Imaging.
[46] W. Willett,et al. PrimeScreen, a brief dietary screening tool: reproducibility and comparability with both a longer food frequency questionnaire and biomarkers , 2001, Public Health Nutrition.
[47] G. Dalsky,et al. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. , 1993, The Journal of pediatrics.